Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trials

Long, 2015, Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial, Lancet, 386, 444, 10.1016/S0140-6736(15)60898-4 Robert, 2015, Improved overall survival in melanoma with combined dabrafenib and trametinib, N Engl J Med, 372, 30, 10.1056/NEJMoa1412690 Weber, 2015, Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial, Lancet Oncol, 16, 375, 10.1016/S1470-2045(15)70076-8 Robert, 2015, Pembrolizumab versus ipilimumab in advanced melanoma, N Engl J Med, 372, 2521, 10.1056/NEJMoa1503093 Hodi, 2016, Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial, Lancet Oncol, 17, 1558, 10.1016/S1470-2045(16)30366-7 Ascierto, 2016, Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial, Lancet Oncol, 17, 1248, 10.1016/S1470-2045(16)30122-X Long, 2017, Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/k–mutant melanoma: long-term survival and safety analysis of a phase 3 study, Ann Oncol, 10.1093/annonc/mdx176 Robert, 2015, Eur J Cancer, 51 Weber J, Minor D, D'Angelo S, Neyns B, Smylie M, Miller W, et al. Overall survival in patients with advanced melanoma who received nivolumab vs investigator's choice chemotherapy in the phase 3 CheckMate 037 trial. Oral presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA. Schachter, 2016, Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival analysis of KEYNOTE-006, ASCO Meet Abstr, 34, 9504 Ascierto, 2016, Prognostic subgroups and impact of treatment for post-progression overall survival in patients with BRAFV600-mutated metastatic melanoma treated with dacarbazine or vemurafenib ± cobimetinib: a pooled analysis, Ann Oncol, 27, vi394 Ribas, 2016, Pembrolizumab (pembro) in combination with dabrafenib (D) and trametinib (T) for BRAF-mutant advanced melanoma: phase 1 KEYNOTE-022 study, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.3014 Ribas, 2015, Phase I study combining anti-PD-L1 (MEDI4736) with BRAF (dabrafenib) and/or MEK (trametinib) inhibitors in advanced melanoma, J Clin Oncol, 33, 10.1200/jco.2015.33.15_suppl.3003 Hwu, 2016, Preliminary safety and clinical activity of atezolizumab combined with cobimetinib and vemurafenib in BRAF V600-mutant metastatic melanoma, Ann Oncol, 27, vi381 Long, 2016, Factors predictive of response, disease progression, and overall survival after dabrafenib and trametinib combination treatment: a pooled analysis of individual patient data from randomised trials, Lancet Oncol, 17, 1743, 10.1016/S1470-2045(16)30578-2 Long, 2014, Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma, N Engl J Med, 371, 1877, 10.1056/NEJMoa1406037 Balch, 2009, Final version of 2009 AJCC melanoma staging and classification, J Clin Oncol, 27, 6199, 10.1200/JCO.2009.23.4799 Cox, 1984 Therneau, 2001 Atkinson EJ, Therneau TM. An introduction to recursive partitioning using the RPART routines. Mayo Foundation http://www.mayo.edu/research/documents/biostat-61pdf/doc-10026699. [Accessed 15 February 16]. Long, 2016, Overall survival and durable responses in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib combined with trametinib, J Clin Oncol, 34, 871, 10.1200/JCO.2015.62.9345 Menzies, 2015, Clinicopathologic features associated with efficacy and long-term survival in metastatic melanoma patients treated with BRAF or combined BRAF and MEK inhibitors, Cancer, 121, 3826, 10.1002/cncr.29586 Larkin, 2016, Clinical predictors of response for coBRIM: a phase III study of cobimetinib (C) in combination with vemurafenib (V) in advanced BRAF-mutated melanoma (MM), J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.9528 Ascierto PA, Dréno B, Larkin J, McArthur GA, Danielli R, Demidov L, et al. Clinical predictors of survival with cobimetinib combined with vemurafenib: pooled analysis from BRIM-7 and coBRIM. Poster presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA. McArthur, 2016, Efficacy of cobimetinib (C) and vemurafenib (V) in advanced BRAF-mutated melanoma patients (pts) with poor and favorable prognosis in the coBRIM phase III study, J Clin Oncol, 34, 10.1200/JCO.2016.34.15_suppl.9530 Weide, 2016, Baseline biomarkers for outcome of melanoma patients treated with pembrolizumab, Clin Cancer Res, 22, 5487, 10.1158/1078-0432.CCR-16-0127 Rai, 2016, Safety and efficacy of anti-PD-1 antibodies in elderly patients with metastatic melanoma, Ann Oncol, 27, iv382 Larkin J, Ferrucci PF, Gonzalez R, Thomas L, Maio M, Hill A, et al. Efficacy of nivolumab plus ipilimumab combination in patients with advanced melanoma and elevated serum lactate dehydrogenase: a pooled analysis. Oral presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA. Blank C, Ribas A, Long GV, Mortier L, Carlino MS, Lotem M, et al. Impact of baseline serum lactate dehydrogenase concentration on efficacy in the KEYNOTE-006 study of pembrolizumab vs ipilimumab. Poster presentation at: Society for Melanoma Research Congress; November 6–9, 2016; Boston, MA. Long, 2017, Impact of baseline serum LDH concentration on the efficacy of pembrolizumab and ipilimumab in patients with advanced melanoma: data from KEYNOTE-006, Eur J Cancer, 72